News & Events
Dr. Jordy Miller, Ph.D., Mayo Clinic, Rochester, Min., discusses his team’s research effort to test the safety of an investigational drug in heart valve disease patients in slowing progression of stenosis, an abnormal narrowing of vessels or other structures.
Calcific aortic valve stenosis is a condition in which the heart valve to the aorta narrows and cannot open fully. Less than 40 percent of patients with valve stenosis survive for five years after being diagnosed, and surgical replacement of the heart valve is the only accepted treatment to extend a patient’s life. This unique NIH funding mechanism will allow us to rapidly translate basic science findings to a clinical trial of a Sanofi investigational drug, with the overall goal of slowing progression of valve disease and prolonging the lives of these patients.